AASLD GUIDELINES Bundle (free trial)

AASLD Hepatitis C

AASLD GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/53004

Contents of this Issue

Navigation

Page 10 of 17

Figure 3. Managing and Treating Patients with Chronic HCV Infection, Genotype 4 Eligible Patient Anti-HCV Positive Determine quantitative HCV RNA Determine HCV genotype If genotype 4 More than portal fibrosis Liver biopsy suggested Treat with PegIFN plus RBV, 1000 mg ≤ 75 kg; 1200 mg > 75 kg Determine quantitative HCV RNA at week 12 Complete EVR (HCV RNA negative) (HCV RNA $> 2 log) Partial EVR Determine qualitative HCV RNA at week 24 Continue treatment for a total of 48 weeks HCV RNA negative Qualitative HCV RNA at week 72 (to establish SVR) HCV RNA positive Stop treatment (HCV RNA $< 2 log) No EVR No fibrosis or portal fibrosis only Consider no treatment 9

Articles in this issue

Archives of this issue

view archives of AASLD GUIDELINES Bundle (free trial) - AASLD Hepatitis C